Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
Author:
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy
Reference53 articles.
1. How to use new biology to guide therapy in multiple myeloma;Morgan;Hematol Am Soc Hematol Educ Progr.,2012
2. Multiple myeloma;Palumbo;N Engl J Med.,2011
3. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site;Zelle-Rieser;J Hematol Oncol,2016
4. Cytokines in cancer pathogenesis and cancer therapy;Dranoff;Nat Rev Cancer,2004
5. Cancer prevention by vaccination against hepatitis B;Chang;Cancer Prevention II: Recent Results Cancer Res.,2009
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PD-L1 and PD-1 in immune regulation and their implications in blood cancers;Advances in Cancer Biology - Metastasis;2024-10
2. Rediscovering hemostasis abnormalities in multiple myeloma: The new era;Heliyon;2024-07
3. Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study;Clinical Lymphoma Myeloma and Leukemia;2024-05
4. Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapy;Blood;2024-01-11
5. TTK/MPS1 inhibitor OSU-13 targets the mitotic checkpoint and is a potential therapeutic strategy for myeloma;Haematologica;2023-07-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3